Weekly Paclitaxel as Third-line Chemotherapy in Patients With Metastatic Transitional Cell Carcinoma of Urothelial Tract: Results of a Phase II Study

被引：0
|
作者：
Rozzi, A. [1 ]
Nardoni, C. [1 ]
Corona, M. [1 ]
Falbo, T. [2 ]
De Marco, F. [3 ]
Grillenzoni, L. [3 ]
Lanzetta, G. [4 ]
机构：
[1] Ist Neurotraumatol, Clin Oncol Unit, I-00185 Grottaferrata, Italy
[2] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy
[3] Ist Neurotraumatol Italiano INI Grottaferrata, Div Urol, Rome, Italy
[4] Ist Neurotraumatol Italiano INI Grottaferrata, Clin Oncol Unit, Rome, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72059-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S518 / S518
页数：1
相关论文
共 50 条
  • [31] Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma
    Ogawa, Masahiro
    Yamamoto, Shinya
    Inoue, Toru
    Numao, Noboru
    Yuasa, Takeshi
    Masuda, Hitoshi
    Fukui, Iwao
    Yonese, Junji
    ANTICANCER RESEARCH, 2020, 40 (03) : 1613 - 1618
  • [32] Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study
    Brandes, AA
    Basso, U
    Vastola, E
    Tosoni, A
    Pasetto, LA
    Jirillo, A
    Lonardi, S
    Paris, MK
    Koussis, H
    Monfardini, S
    Ermani, M
    ANNALS OF ONCOLOGY, 2003, 14 (12) : 1727 - 1731
  • [33] Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: A phase II study
    Halim, Amal
    Abotouk, Niveen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 (01) : 60 - 65
  • [34] Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
    Rosenberg, J. E.
    Halabi, S.
    Sanford, B. L.
    Himelstein, A. L.
    Atkins, J. N.
    Hohl, R. J.
    Millard, F.
    Bajorin, D. F.
    Small, E. J.
    ANNALS OF ONCOLOGY, 2008, 19 (05) : 946 - 950
  • [35] Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial
    CC Zielinski
    B Schnack
    M Grbovic
    T Brodowicz
    C Wiltschke
    G Steger
    H Pflüger
    M Marberger
    British Journal of Cancer, 1998, 78 : 370 - 374
  • [36] Weekly paclitaxel in metastatic breast cancer patients: A phase II study
    Gori, S
    Mosconi, AM
    Basurto, C
    Cherubini, R
    De Angelis, V
    Tonato, M
    Colozza, M
    TUMORI, 2002, 88 (06) : 470 - 473
  • [37] Paclitaxel and carboplatin in patients with metastatic urothelial cancer:: Results of a phase II trial
    Zielinski, CC
    Schnack, B
    Grbovic, M
    Brodowicz, T
    Wiltschke, C
    Steger, G
    Pflüger, H
    Marberger, M
    BRITISH JOURNAL OF CANCER, 1998, 78 (03) : 370 - 374
  • [38] Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy
    Rivera, E
    Holmes, FA
    Frye, D
    Valero, V
    Theriault, RL
    Booser, D
    Walters, R
    Buzdar, AU
    Dhingra, K
    Fraschini, G
    Hortobagyi, GN
    CANCER, 2000, 89 (11) : 2195 - 2201
  • [39] Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: A phase II study of the SUOC group
    Kitamura, Hiroshi
    Taguchi, Keisuke
    Kunishima, Yasuharu
    Yanase, Masahiro
    Takahashi, Atsushi
    Shigyo, Masanori
    Tanaka, Toshiaki
    Mutoh, Masatoshi
    Fukuta, Fumimasa
    Masumori, Naoya
    Tsukamoto, Taiji
    CANCER SCIENCE, 2011, 102 (06) : 1171 - 1175
  • [40] Clinical benefit of second line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study.
    Joly, F
    Tchen, N
    Chevreau, C
    Henry-Amar, M
    Priou, F
    Chinet-Charrot, P
    Rolland, F
    Droz, JP
    Journet, V
    Culine, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 411S - 411S
12345